Valuation : Alkermes plc

Market Cap 786.47Cr 676.76Cr 636.74Cr 581.66Cr 1.09TCr 74TCr 1.09TCr 7.52TCr 2.92TCr 38TCr 2.95TCr 2.89TCr 1,22700Cr P/E 2026 *
-91.9x
P/E 2027 * 64.5x
Enterprise Value 860.87Cr 740.78Cr 696.97Cr 636.68Cr 1.19TCr 81TCr 1.19TCr 8.24TCr 3.2TCr 42TCr 3.23TCr 3.16TCr 1,34300Cr EV / Sales 2026 *
4.72x
EV / Sales 2027 * 4.39x
Free-Float
89.45%
Yield 2026 *
-
Yield 2027 * -
1 day-1.00%
1 week-2.18%
Current month-1.31%
1 month-6.63%
3 months+6.90%
6 months+58.38%
Current year+65.74%
1 week 45.8
Extreme 45.8
48.74
1 month 45.8
Extreme 45.8
51.66
Current year 27
Extreme 27
55.67
1 year 25.16
Extreme 25.165
55.67
3 years 22.01
Extreme 22.01
55.67
5 years 21.24
Extreme 21.24
55.67
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 53 01/08/2026
Director of Finance/CFO 53 15/09/2025
Chief Tech/Sci/R&D Officer 58 30/05/2017
Director TitleAgeSince
Chairman 64 01/09/2011
Director/Board Member 74 26/05/2016
Director/Board Member 63 30/03/2018
Date Insider Type Main position Quantity % Market Cap. Importance
01/09/26 Exercice

Chief Technology Officer

19,000 0.0113%
17/08/26 Sell

Executive/Senior Manager

-7,576 0.0045%
05/08/26 Free

Chief Executive Officer

2,17,534 0.1297%
Change 5-day change 1-year change 3-year change Capi.($)
-1.00%-2.18%+60.36%+58.87% 786.47Cr
-2.54%-2.84%-1.90%+14.52% 5.03TCr
-1.15%+0.30%+435.30%+518.88% 4.52TCr
-1.53%+2.10%+45.18%+20.98% 4.47TCr
-1.25%-2.12%+12.62%+75.24% 4.12TCr
+0.53%-1.67%+15.16%+49.88% 3.31TCr
-0.99%+8.10% - - 1.78TCr
-0.18%-1.14%+23.11%+123.99% 1.66TCr
-1.01%+0.50%+15.83%+27.98% 1.48TCr
-1.44%-0.57%+78.57%+41.87% 1.4TCr
Average -1.06%-0.40%+76.02%+103.58% 2.86TCr
Weighted average by Cap. -1.23%-0.56%+92.65%+124.68%

Financials

2026 *2027 *
Net sales 182.49Cr 157.03Cr 147.75Cr 134.97Cr 252.48Cr 17TCr 253.17Cr 1.75TCr 677.48Cr 8.84TCr 685.27Cr 670.33Cr 28TCr 194.48Cr 167.35Cr 157.46Cr 143.84Cr 269.08Cr 18TCr 269.81Cr 1.86TCr 722.01Cr 9.42TCr 730.31Cr 714.38Cr 30TCr
Net income -8.99Cr -7.74Cr -7.28Cr -6.65Cr -12Cr -848.98Cr -12Cr -86Cr -33Cr -435.59Cr -34Cr -33Cr -1.4TCr 12Cr 10Cr 9.74Cr 8.9Cr 17Cr 1.14TCr 17Cr 115.08Cr 45Cr 582.69Cr 45Cr 44Cr 1.88TCr
Net Debt 74Cr 64Cr 60Cr 55Cr 102.92Cr 7.02TCr 103.2Cr 711.7Cr 276.17Cr 3.6TCr 279.35Cr 273.26Cr 12TCr 67Cr 58Cr 54Cr 50Cr 93Cr 6.33TCr 93Cr 640.91Cr 248.7Cr 3.25TCr 251.56Cr 246.08Cr 10TCr
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
04/26/04 $46.38 -1.08% 2,74,722
03/26/03 $46.88 -1.76% 9,74,512
02/26/02 $47.72 +1.10% 15,66,413
01/26/01 $47.20 +0.45% 13,51,261
31/26/31 $46.99 -0.89% 14,40,889
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
46.88USD
Average target price
56.00USD
Spread / Average Target
+19.45%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALKS Stock